Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Contrast Induced Nephropathy - Overview
Contrast Induced Nephropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Contrast Induced Nephropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Contrast Induced Nephropathy - Companies Involved in Therapeutics Development
Daiichi Sankyo Co Ltd
Pharming Group NV
Radikal Therapeutics Inc
Saghmos Therapeutics Inc
Contrast Induced Nephropathy - Drug Profiles
carperitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conestat alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-62516 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Contrast Induced Nephropathy - Dormant Projects
Contrast Induced Nephropathy - Discontinued Products
Contrast Induced Nephropathy - Product Development Milestones
Featured News & Press Releases
Oct 17, 2018: Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST) in Contrast-induced Nephropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Contrast Induced Nephropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Contrast Induced Nephropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Contrast Induced Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Contrast Induced Nephropathy - Pipeline by Pharming Group NV, H1 2020
Contrast Induced Nephropathy - Pipeline by Radikal Therapeutics Inc, H1 2020
Contrast Induced Nephropathy - Pipeline by Saghmos Therapeutics Inc, H1 2020
Contrast Induced Nephropathy - Dormant Projects, H1 2020
Contrast Induced Nephropathy - Discontinued Products, H1 2020